The gene editing tool known as CRISPR-Cas9 is changing what’s possible for treating a wide range of diseases caused by ...

The real revolution came in 2012, when researchers Jennifer Doudna and Emmanuelle Charpentier harnessed CRISPR, a natural bacterial defense system. In bacteria, CRISPR cuts out invading viruses’ DNA ...

A leading bioethicist at Hiroshima University is calling for an anticipatory, rather than reactive, approach to ethics after ...

One person's side effect could be another person's treatment if we expand our perspective on small molecule drug targets, ...

A leading bioethicist at Hiroshima University is calling for an anticipatory, rather than reactive, approach to ethics after a Japanese government ...

CRISPR-based technology is advancing rapidly, driving international competition. Its promise to transform medicine is colliding with political and social realities, even as applications expand.

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

In biotech, success often begins in the lab — and for CRISPR pioneers, every clinical trial feels like a moonshot.

According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...

CompletedstrategicpivotfromR&Dfocustocommercial focusRebranded as Dyadic Applied BioSolutions and launched redesigned website ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Intellia Therapeutics (NASDAQ: NTLA) underwent analysis by 21 analysts in the last quarter, revealing a spectrum of ...